ArticlePloS one2013
A high frequency of circulating th22 and th17 cells in patients with new onset graves' disease.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02316691 (B-cell Depletion Therapy With Rituximab for Thyroid Eye Disease), which is not on this map. Cited by 46 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
B-cell Depletion Therapy With Rituximab for Thyroid Eye Disease
Who cites it
46 citing papers in PubMed, 1 synthesis or guideline pooled it, 83 citations in OpenAlex.
- Pooled it
- Altered balance between self-reactive T helper (Th)17 cells and Th10 cells and between full-length forkhead box protein 3 (FoxP3) and FoxP3 splice variants in Hashimoto's thyroiditis.Clinical and experimental immunology · 2015Trial
- Expression levels of T cell-related immune factors and their correlation with thyroid function in Graves' disease with varied serum iodine status: insights into immunopathogenesis.Frontiers in endocrinology · 2025Article
- Th17-associated cytokine gene hypomethylation reflects epigenetic dysregulation in graves' disease.Frontiers in immunology · 2025Article
- The changing landscape of thyroid eye disease: current clinical advances and future outlook.Eye (London, England) · 2024Review
- Effect of methimazole treatment on Th1, Th17, and Th22 lymphocytes in pediatric Graves' disease patients.Frontiers in immunology · 2024Article
- Study on serum TL1A levels and their correlation with Th17 cells, IL-17 and IL-21 in children with Graves' disease.Frontiers in immunology · 2024Article
- Th17 cytokines and factors modulating their activity in patients with pernicious anemia.Immunologic research · 2023Article
- Characterizing the Interplay of Lymphocytes in Graves' Disease.International journal of molecular sciences · 2023Review
- Stress-Related Immune Response and Selenium Status in Autoimmune Thyroid Disease Patients.International journal of molecular sciences · 2023Article
- Comprehensive immunophenotypic analysis reveals the pathological involvement of Th17 cells in Graves' disease.Scientific reports · 2022Article
- 2021 update on thyroid-associated ophthalmopathy.Journal of endocrinological investigation · 2022Review
- Peripheral immunophenotyping of AITD subjects reveals alterations in immune cells in pediatric vs adult-onset AITD.iScience · 2022Article
- Changes in Th9 and Th17 lymphocytes and functional cytokines and their relationship with thyroid-stimulating hormone receptor antibodies at different stages of graves' disease.Frontiers in immunology · 2022Article
- Gut Microbiome and the Role of Metabolites in the Study of Graves' Disease.Frontiers in molecular biosciences · 2022Review
- Plasma levels of Th17-associated cytokines and selenium status in autoimmune thyroid diseases.Immunity, inflammation and disease · 2021Article
- Immune mechanisms involved in the coexistence of oral lichen planus and autoimmune thyroid diseases.Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2021Article
- Decreased Treg Cell and TCR Expansion Are Involved in Long-Lasting Graves' Disease.Frontiers in endocrinology · 2021Article
- Identification of lncRNA and mRNA Expression Profile in Relapsed Graves' Disease.Frontiers in cell and developmental biology · 2021Article
- Role of Th22 Cells in the Pathogenesis of Autoimmune Diseases.Frontiers in immunology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
T-helper (Th) 22 and Th17 cells are involved in the pathogenesis of autoimmune diseases. However, their roles in the pathogenesis of Graves'disease (GD) are unclear. This study is aimed at examining the frequency of peripheral blood Th22, Th17, and Th1 cells and the levels of plasma IL-22, IL-17, and IFN-γ in patients with GD. A total of 27 patients with new onset GD and 27 gender- and age-matched healthy controls (HC) were examined for the frequency of peripheral blood Th22, Th17, and IFN-γ cells by flow cytometry. The concentrations of plasma IL-22, IL-17, and IFN-γ were examined by enzyme-linked immunosorbent assay. The levels of serum TSHR antibodies (A-TSHR), free triiodothyronine (FT3), free thyroxine (FT4), and thyroid stimulating hormone (TSH) were examined by radioimmunoassay and chemiluminescent assay, respectively. The levels of serum TSAb were examined by enzyme-linked immunosorbent assay. In comparison with those in the HC, significantly elevated percentages of Th22 and Th17 cells, but not Th1 cells, and increased levels of plasma IL-22 and IL-17, but not IFN-γ, were detected in GD patients (P<0.0001, for both). The percentages of both Th22 and Th17 cells and the levels of plasma IL-22 and IL-17 were correlated positively with the levels of serum TSAb in GD patients (r = 0.7944, P<0.0001; r = 0.8110, P<0.0001; r = 0.7101, p<0.0001; r = 0.7407, p<0.0001, respectively). Th22 and Th17 cells may contribute to the pathogenesis of GD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.